COVID-19 – Global Information
The National Comprehensive Cancer Network (NCCN) has recommended that patients receiving active cancer treatment should be prioritized for vaccination against COVID-19. Read more.
Two studies published today in Blood Advances suggest people with blood type O may have a lower risk of COVID-19 infection and reduced likelihood of severe outcomes, including organ complications, if they do get sick. Read more.
Read this summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic published by The Lancet Oncology. Read more.
PatientView has been researching the views and needs of patient groups worldwide and they are using their network to track the needs and actions of patient groups as they adapt to the demands of Covid-19 by collating the various communications and tweets under the hashtag #PAGC19. Read more.
The pharmaceutical company, Karyopharm Therapeutics has announced plans to initiate a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19 (coronavirus). Selinexor, marketed as XPOVIO®, is currently approved at higher doses by the Food and Drug Administration (FDA) as a treatment for patients with relapsed or refractory multiple myeloma. Read more.
Many WECAN member organisations are providing informational resources about COVID-19 and about specific recommendations to their patient community. Here you find links to the COVID-19 resources provided on the websites of those patient organisations, which may link to additional relevant articles and tools for their specific disease area. Read more.
Recording of the webinar held by the International Academy for Clinical Hematology (IACH)on COVID-19. The webinar was given by Prof. Mohamad Mohty and Prof. Marivi Mateos. Watch it here.
These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of myeloma patients. Read more.